Bleeds in hemophilia are treated either on demand or prophylactically by intravenous
replacement therapy with FVIII or FIX. However, there is a call for subcutaneous and less
frequent drug administration, and this need may be met by administration of a suitable
antibody. Pioneering studies in vitro [